Facebook
Twitter
LinkedIn
Forward
Emerging Role of CT and MR-Guided Online Adaptive Radiotherapy for Upper GI Malignancies
Online adaptive radiotherapy (ART) is a current and emerging technology and approach that leverages CT and MR images obtained on the treatment delivery platform to personalized daily RT fractions to account for organ and tumor motion, deformation, and positioning with the potential of improving outcomes such as survival and toxicity. Upper abdominal gastrointestinal GI sites have been identified as ideal clinical scenarios for online ART for several reasons. CT and MR based online ART each have unique advantages and disadvantages that might make one approach better than the other one in unique situations. In addition, both online ART platforms require more intensive engagement of the radiation oncologist, physicist, dosimetrist, and therapist on the treatment console, analogous to performing a surgical procedure. Due to time and resource intensive nature of this process, the existing RT workflow often does not allow the treating physician and team to be the same team that performs these important tasks before treatment delivery. Therefore, a well-conceived and standardized sign-out process with essential transfer of critical information is necessary to ensure that the online ART team achieve the treatment intent and intended prioritization of tumor or organs at risk objectives daily. Both CT and MR based online ART have unique physics and quality assurance requirements necessary to ensure safe and optimal treatment for each fraction delivered. Finally, both CT and MR based online ART can leverage AI to expedite the online ART process and expand its role to more complex treatments.
Topics:
- CT-Based Online Adaptive Radiotherapy for Upper GI Cancers
Lauren Henke, MD, MSCI - MR-based Online Adaptive Radiotherapy for Upper GI Cancers
Jessica Frakes, MD - Artificial Intelligence and Online ART: What are its Capabilities and Role of Human Expertise in AI-Enabled ART?
Borna Maraghechi, PhD - Q and A
Full Panel
This activity is available from February 6, 2024, through 11:59 p.m. Eastern time on February 5, 2026.
This activity was originally recorded at the 2023 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of radiation oncologists, physicists, radiation dosimetrists, radiation therapists, and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the current state of online ART including both CT and MR based approaches, their trade-offs, as well as existing evidence for their added value in GI and non-GI disease sites.
- Discuss the radiation oncologist's role in signing out to the online ART team and identify what critical information needs to be transferred to accomplish the stated goals of the treatment.
- Explain how AI can expedite the online ART process in the future, possibly reducing the need for a dedicated online ART team, and the role of the human interaction in optimizing the AI-enabled online ART treatment.
- Percy Lee, MD, FASTRO, is employed by City of Hope National Medical Center and Orange County Lennar Foundation Cancer Center. Dr. Lee receives consulting fees/honoraria from AstraZeneca, RTOG Foundation, Varian, Inc., and Viewray. Dr. Lee serves on the Independent Data Monitoring Committee for Roche and Genentech.
- Lauren E. Henke, MD, MS, is employed by University Hospitals Seidman Cancer Center, Case Western Reserve University. Dr. Henke receives research funding from Varian. She receives honoraria from ViewRay and LusoPalex.
- Jessica M. Frakes, MD, is employed by H. Lee Moffitt Cancer Center and Research Institute. Dr. Frakes receives honoraria/consulting fees from Boston Scientific and ViewRay.
- Borna Maraghechi, PhD, is employed by Washington University School of Medicine in St. Louis.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until February 6, 2026, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.